{"nctId":"NCT03998163","briefTitle":"CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","startDateStruct":{"date":"2019-05-06","type":"ACTUAL"},"conditions":["Uremic Pruritus"],"count":222,"armGroups":[{"label":"CR845 0.5mcg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: CR845 0.5 mcg/kg"]}],"interventions":[{"name":"CR845 0.5 mcg/kg","otherNames":["CR845","Difelikefalin"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\nTo be eligible for inclusion into the study, a patient must meet the following criteria:\n\n* Has end-stage renal disease (ESRD) and has been on hemodialysis 3 times per week for at least 3 months prior to the start of screening;\n* Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 2 urea reduction ratio measurements ≥65%, or 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis days during the 3 months period prior to screening;\n* Prior to Treatment:\n\n  * Has completed at least 3 Worst Itching Intensity NRS questionnaires from the start of the Run-in Period up to and including the pre-dose assessment on Day 1;\n\nKey Exclusion Criteria:\n\nA patient will be excluded from the study if any of the following criteria are met:\n\n* Known noncompliance with dialysis treatment that in the opinion of the investigator would impede completion or validity of the study;\n* Scheduled to receive a kidney transplant during the study;\n* New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening;\n* New or change of prescription for opioids, gabapentin, or pregabalin within 14 days prior to screening;\n* Received another investigational drug within 30 days or five half-lives (whichever is longer) prior to the start of dosing or is planning to participate in another interventional clinical study while enrolled in this study;\n* Has pruritus only during the dialysis session (by patient report);\n* Is receiving ongoing ultraviolet B treatment and/or anticipates receiving such treatment during the study;\n* Participated in a previous clinical study with CR845.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With AEs.","description":"Assessed by monitoring of adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":222},"commonTop":["Diarrhoea"]}}}